David Cornblath
Neurology · Lutherville, MDNPI 1801843834
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $244,948 of the $344,577 with a category attached, or 71.1%. 21 manufacturers reported payments, led by Pfizer at 32.9% of the total. Reporting peaked in 2021 at $97,020 and has fallen 68.9% since, to $30,180 in 2025. Among neurology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $2801.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$113K
- Seagen Inc.$44K
- Octapharma USA, Inc.$29K
- Sanofi$29K
- Boehringer Ingelheim International GmbH$22K
- Sanofi US Services Inc.$21K
- plus $86K from 15 others
Across 2 payments — averaging $3396.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotest AG$4K
- Pfizer$3K
What the payments were for
- Royalty or licence$1670%
- Consulting fees$244,94871%
- Speaking & faculty fees$58,14117%
- Travel & lodging$40,48112%
- Food & beverage$8380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 25 | $113,339 |
| Seagen Inc. | 9 | $44,480 |
| Octapharma USA, Inc. | 16 | $29,066 |
| Sanofi | 4 | $28,590 |
| Boehringer Ingelheim International GmbH | 4 | $22,125 |
| Sanofi US Services Inc. | 9 | $21,342 |
| CSL Behring | 11 | $15,091 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 7 | $10,825 |
| Grifols, S.A. | 3 | $9,893 |
| Boehringer Ingelheim | 2 | $9,840 |
| F. Hoffmann-la Roche AG | 3 | $6,600 |
| Janssen Research & Development, LLC | 5 | $4,750 |
| UCB SA | 1 | $4,538 |
| AstraZeneca | 3 | $4,537 |
| Alnylam Pharmaceuticals Inc. | 4 | $4,250 |
| Tanabe Pharma America, Inc. | 7 | $4,167 |
| Argenx US, Inc. | 5 | $3,514 |
| Amgen | 1 | $2,880 |
| Janssen Global Services, LLC | 1 | $2,475 |
| Genentech, Inc. | 1 | $2,100 |
| UCB, Inc. | 2 | $176 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANZYGA$24,551
- VYNDAQEL$22,922
- Hizentra$14,956
- TIVDAK$8,160
- Privigen$4,603
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$3,900
- VYVGART$3,375
- Gamunex-C$3,000
- SPIRIVA RESPIMAT$2,250
- NO PRODUCT DISCUSSED$2,012
- ERAXIS$1,600
How this compares
$344,577 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.
Other neurology in Lutherville
- Daniel BeckerLutherville$1.6M
- Bruce RabinLutherville$228K
- Sangjin OhGlen Burnie$1.5M
- Pavel KleinBethesda$709K
- Ruwani GunawardaneFulton$479K
- Michael PolydefkisBaltimore$371K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Thomas CrawfordBaltimore$215K
- Boyd DwyerFrederick$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.